Plain-English translation of NCT05294055 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Myeloma research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing mecapegfilgrastim, a medication that helps your bone marrow produce more blood-forming stem cells. Patients with multiple myeloma or lymphoma who are candidates for stem cell transplant will receive chemotherapy followed by the medication on either day 2 or day 5 after treatment. Researchers want to know which timing works best to collect enough stem cells for your transplant in as few collection sessions as possible.
Stem cell transplants can help treat multiple myeloma and lymphoma, but the challenge is collecting enough healthy stem cells from patients' blood. This medication is designed to boost stem cell production, and this trial is testing whether the timing of when you receive it makes a difference in how successfully cells can be collected.
You likely qualify if…
You likely don't qualify if…
You will receive high-dose chemotherapy, then be randomly assigned to receive the growth-factor medication either on day 2 or day 5 after chemotherapy. Over the next several days, you will undergo apheresis (a procedure where blood is drawn, stem cells are separated out, and the rest of your blood is returned to you) up to three times to collect enough stem cells. Your doctor will monitor your blood counts and overall health throughout this process.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
China